Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Sold by Two Sigma Advisers LP

Two Sigma Advisers LP lowered its position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 2.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 881,783 shares of the medical device company’s stock after selling 20,100 shares during the quarter. Two Sigma Advisers LP owned 1.34% of Tandem Diabetes Care worth $31,762,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. grew its stake in Tandem Diabetes Care by 1.1% in the 4th quarter. Vanguard Group Inc. now owns 7,440,005 shares of the medical device company’s stock valued at $267,989,000 after acquiring an additional 77,451 shares during the last quarter. ArrowMark Colorado Holdings LLC raised its position in Tandem Diabetes Care by 14.1% during the fourth quarter. ArrowMark Colorado Holdings LLC now owns 2,723,715 shares of the medical device company’s stock worth $98,108,000 after acquiring an additional 337,026 shares during the last quarter. GW&K Investment Management LLC lifted its holdings in shares of Tandem Diabetes Care by 18.0% in the fourth quarter. GW&K Investment Management LLC now owns 2,123,488 shares of the medical device company’s stock valued at $76,488,000 after purchasing an additional 323,674 shares in the last quarter. Jacobs Levy Equity Management Inc. grew its position in shares of Tandem Diabetes Care by 189.0% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 1,661,013 shares of the medical device company’s stock valued at $59,830,000 after purchasing an additional 1,086,337 shares during the last quarter. Finally, Park West Asset Management LLC grew its position in shares of Tandem Diabetes Care by 49.5% in the fourth quarter. Park West Asset Management LLC now owns 1,600,000 shares of the medical device company’s stock valued at $57,632,000 after purchasing an additional 530,000 shares during the last quarter.

Insider Activity at Tandem Diabetes Care

In other Tandem Diabetes Care news, COO Jean-Claude Kyrillos purchased 10,538 shares of the business’s stock in a transaction that occurred on Friday, March 7th. The shares were purchased at an average price of $18.12 per share, for a total transaction of $190,948.56. Following the completion of the acquisition, the chief operating officer now owns 10,538 shares of the company’s stock, valued at approximately $190,948.56. This represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.90% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on TNDM shares. Canaccord Genuity Group lifted their price objective on Tandem Diabetes Care from $58.00 to $59.00 and gave the stock a “buy” rating in a research report on Thursday, May 1st. Royal Bank of Canada dropped their price target on Tandem Diabetes Care from $65.00 to $55.00 and set an “outperform” rating for the company in a research report on Thursday, February 27th. Wells Fargo & Company cut their price target on Tandem Diabetes Care from $22.00 to $20.00 and set an “equal weight” rating for the company in a report on Thursday, May 1st. Stifel Nicolaus decreased their price objective on Tandem Diabetes Care from $60.00 to $31.00 and set a “buy” rating on the stock in a research note on Thursday, May 1st. Finally, The Goldman Sachs Group dropped their price objective on Tandem Diabetes Care from $42.00 to $24.00 and set a “neutral” rating for the company in a research report on Monday, March 3rd. Eight research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, Tandem Diabetes Care currently has an average rating of “Moderate Buy” and an average price target of $39.81.

Tandem Diabetes Care Price Performance

TNDM opened at $23.52 on Wednesday. Tandem Diabetes Care, Inc. has a 1 year low of $15.75 and a 1 year high of $53.69. The company’s 50 day simple moving average is $19.31 and its 200 day simple moving average is $27.72. The stock has a market capitalization of $1.57 billion, a PE ratio of -12.19 and a beta of 1.47. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.32 and a current ratio of 2.90.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its quarterly earnings results on Wednesday, April 30th. The medical device company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.07). The company had revenue of $234.42 million for the quarter, compared to analysts’ expectations of $220.19 million. Tandem Diabetes Care had a negative return on equity of 44.19% and a negative net margin of 14.84%. The business’s revenue for the quarter was up 22.3% on a year-over-year basis. During the same period in the prior year, the business earned ($0.65) EPS. As a group, sell-side analysts expect that Tandem Diabetes Care, Inc. will post -1.68 EPS for the current year.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.